Shareholder Primacy Podcast Episode Summary

Podcast: Shareholder Primacy
Host: Free Float Media Inc.
Episode: Legal and financial questions of Pfizer-Novo-Metsera
Date: November 12, 2025
Hosts: Mike Levin (activist investor), Ann Lipton (law professor, University of Colorado)

Episode Overview

This episode delves into the fierce bidding war—and subsequent legal drama—surrounding Pfizer and Novo Nordisk's competing attempts to acquire Medcera, a newly public and venture-backed drug company with a promising weight loss drug in development. The hosts break down the financial, regulatory, and legal maneuvering that defined the deal, focusing on antitrust considerations, merger contract terms, and the resulting high-stakes litigation.

Key Discussion Points and Insights

1. Background on the Companies and the Deal

• Pfizer: Major US-based pharmaceutical company, famous for Covid vaccines, but lacks a GLP-1 weight loss drug in its portfolio.
• Novo Nordisk: Danish pharma giant, dominant in Denmark’s economy, creator of weight loss blockbusters Ozempic and Wegovy.
  • Recently faced share price struggles, but extremely valuable and influential.
• Medcera:
  • Newly public (IPO in January), no real revenues, “drug developer with a promising drug, though not… assured” ([05:52], A).
  • Heavily VC-backed, with concentrated voting power in two large funds and founders.
  • Was negotiating mergers even during its IPO process.
• Deal Process:
  • Both Pfizer and Novo bid similar price structures: cash plus a contingent value right (CVR) depending on drug milestones.
  • Both sides offered versions of a “public earn-out”—additional payments if Medcera's drugs hit development or regulatory milestones.

2. Financial Terms and Bidding War

• Bids and Structure:
  • Novo: $50/share cash + up to $37 CVR.
  • Pfizer: $47.50/share cash + $22.50 CVR ([08:04], B).
  • Novo’s bid “was absolutely higher by any measure” but carried regulatory risk.
• Pfizer ultimately prevailed: Forced to increase its bid by $2.7 billion over the initial bid ([01:43], A) due to competitive pressure.

3. Antitrust Risk and Legal Innovation

• Antitrust Risk:
  • Key barrier for Novo: already dominates in GLP-1 drugs, so a Medcera buyout likely triggers regulatory scrutiny.
  • Pfizer, by contrast, faces little risk due to lack of drug overlap.
• Hart-Scott-Rodino Act (HSR):
  • Requires pre-clearance for mergers above certain thresholds, focusing on acquisition of “assets or voting control” ([09:01], B).
• Novo’s Two-Step “Workaround”:
  • Proposed up-front cash payment for non-voting stock, reasoning that HSR covers voting but not non-voting control.
  • Potentially avoids pre-clearance; if the second step (full acquisition) is blocked, Novo keeps half the company (non-voting).

4. Legal Concerns with Novo’s Structure

• Risks Identified by Medcera:
  • Concern that the FTC (or DOJ) would treat the structure as an unlawful evasion of HSR ([13:33], B).
  • DOJ has previously fined companies for similar workarounds.
  • Medcera’s official proxy: “risk that the payment of the initial cash consideration and the subsequent payment of the dividend... may not occur.”
• Pfizer’s Strong Merger Agreement:
  • Medcera could only accept a new bid if it was “superior”—with a strict legal definition:
    • “The board has to conclude in good faith that it’s financially superior, taking into account all of the regulatory risks.” ([14:04], B)
    • Must be “about as likely to be completed according to its terms as the Pfizer deal is.”
    • Only breach of fiduciary duty would justify switching deals—a “very high bar” ([16:00], A).

5. Renewed Bidding, Indemnity, and Lawsuits

• Novo Adjusts Its Offer:
  • Matches previous structure, more cash up front, less CVR.
  • Adds wide-ranging indemnification for Medcera’s directors and VC stockholders—protection against litigation and especially government fines.
• Pfizer’s Response:
  • Counters with higher bids and files two lawsuits:
    • Delaware Chancery: alleges Medcera is breaching the merger agreement, Novo’s bid is not “superior” under the contract.
    • Federal court: alleges Novo’s actions are illegally interfering with competition ([18:05], B).
• Role of Indemnity:
  • Shows Medcera (and its backers) didn’t fully trust the government wouldn’t intervene—especially since indemnity covered fines, not just lawsuit damages ([25:05], A/B).

6. Court Proceedings and Regulatory Action

• Delaware Chancery Court (Vice Chancellor Zurn):
  • Refuses to halt the bidding (“last thing a Delaware court’s gonna do is interrupt an active bidding contest” ([29:07], B)).
  • No finding of “bad faith” against Medcera for negotiating; any breach could be compensated later.
  • Result: Pfizer forced to keep outbidding—ultimate “winning” price of $65.50/share + $20.65 CVR ([30:10], A/B).
• FTC Intervention:
  • During government shutdown, FTC warns via letter/phone: two-step non-voting share structure is “really illegal” ([30:21], B).
  • Casts doubt on Medcera’s proxy claim that the regulatory risk had been resolved.
  • “It may not be possible to indemnify for illegal conduct.” ([30:54], B)

7. Aftermath, Takeaways, and Future Litigation

• Pfizer “wins” the deal by paying a huge premium.
  • Closing scheduled for November 13 ([34:27], B).
  • Novo backs off, but Pfizer left with potential claims for damages (“tortious interference”)—unlikely to pursue, but reminiscent of Pennzoil/Texaco in the '80s.
• Potential for Future Disputes:
  • Expected litigation over CVR payouts—“Earn out litigation is going to be what’s left” ([34:41], A).
• Memorable Quotes & Analysis:
  • “The board has to conclude in good faith that the new proposal is so much better... that the regulatory risks are so minimal that it would actually be a breach of fiduciary duty not to take.” ([16:00], B)
  • “That’s a very high bar.” ([16:00], A)
  • “You can’t put that toothpaste back in the tube.” ([25:05], A)
  • “[Novo] call it a bribe to Medcera to get it to terminate the Pfizer deal with no intention of consummating the back half.” ([28:34], B)
  • “Vice Chancellor Zurn… believed, well, I can always fix it later…” ([32:01], B)
  • “It’s great for Medcera shareholders, mostly these VC backers.” ([31:58], B)

Important Segments & Timestamps

• Deal background and players: [03:11] – [06:09]
• Bidding dynamics and CVR structure: [07:14] – [08:54]
• Antitrust risks, HSR Act, and Novo’s workaround: [09:01] – [11:52]
• Merger agreement terms (“superior proposal” definition): [14:04] – [16:04]
• Novo’s indemnity, Pfizer lawsuits, Delaware Chancery: [18:05] – [20:15]
• FTC intervention, government shutdown angle: [24:12] – [31:49]
• Analysis of Chancery Court’s refusal to halt bidding: [29:07] – [32:41]
• Historical comparison (Pennzoil/Texaco case): [33:12] – [33:30]
• Deal closure and leftovers for future litigation: [34:27] – [34:53]

Tone, Color, and Analysis

The hosts blend technical legal and financial insights with casual, sometimes wry commentary. Ann Lipton’s legal acumen grounds the discussion, while Mike Levin’s activist-investor perspective gives color to the strategic and economic stakes. The episode captures how legal nuance, regulatory risk, and tactical aggression collide in a high-profile, high-stakes pharma M&A fight.

Bottom Line:
Pfizer’s hefty win in acquiring Medcera was as much due to effective contract drafting and a sharp understanding of antitrust risk as it was about outbidding. Novo’s aggressive antitrust workaround almost succeeded but was ultimately stopped by regulatory pushback and a carefully locked up merger agreement. The result? A massive payday for Medcera (and its VC backers), with Pfizer perhaps left with lingering annoyance—and the possibility of further litigation.

For more analysis on activist M&A, securities law, and corporate warfare, subscribe to Shareholder Primacy.